gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Brain and acute leukemia, cytoplasmic

BAALC
This gene was identified by gene expression studies in patients with acute myeloid leukemia (AML). The gene is conserved among mammals and is not found in lower organisms. Tissues that express this gene develop from the neuroectoderm. Multiple alternatively spliced transcript variants that encode different proteins have been described for this gene; however, some of the transcript variants are found only in AML cell lines. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: FLT3, HAD, B23, iMpact, MN1
Papers on BAALC
A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia.
New
Nolte et al., Heidelberg, Germany. In Leuk Res, Sep 2015
To identify a more robust risk stratification model, a molecular risk score was developed based on expression levels of the genes BAALC, ERG and WT1.
Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: A meta-analysis.
New
Fu et al., Fuzhou, China. In Mol Clin Oncol, Jul 2015
UNASSIGNED: Numerous studies have investigated the prognostic role of brain and acute leukemia, cytoplasmic (BAALC) gene expression in adult patients with acute myeloid leukemia (AML); however, the results are inconclusive.
mRNA overexpression of BAALC: A novel prognostic factor for pediatric acute lymphoblastic leukemia.
New
Nadimi et al., Eşfahān, Iran. In Biomed Rep, May 2015
UNASSIGNED: BAALC is a novel molecular marker in leukemia that is highly expressed in patients with acute leukemia.
Relation of BAALC and ERG Gene Expression with Overall Survival in Acute Myeloid Leukemia Cases.
Abd El Hameed et al., Cairo, Egypt. In Asian Pac J Cancer Prev, 2014
BACKGROUND: The objectives of this study were to evaluate the expression of brain and acute leukemia, cytoplasmic (BAALC) gene and erythroblast transformation-specific related gene (ERG) in de novo cases of acute myeloid leukemia (AML) and identify roles in disease progression and outcome.
The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Esteve et al., Barcelona, Spain. In Blood Cancer J, 2014
In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients.
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Impact
Bloomfield et al., Columbus, United States. In J Clin Oncol, 2012
Because RUNX1 mutations were more common in older patients and almost never coexisted with NPM1 mutations, RUNX1 mutation-associated expression signatures were derived in older, NPM1 wild-type patients and featured upregulation of genes normally expressed in primitive hematopoietic cells and B-cell progenitors, including DNTT, BAALC, BLNK, CD109, RBPMS, and FLT3, and downregulation of promoters of myelopoiesis, including CEBPA and miR-223.
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
GeneRIF
Heuser et al., Hannover, Germany. In Ann Hematol, 2012
A high MEBE (MN1,ERG, BAALC, EVI1) expression score is an unfavorable prognostic marker in Myelodysplastic syndrome and is associated with an increased risk for progression to Acute myeloid leukemia.
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.
GeneRIF
Bloomfield et al., Columbus, United States. In Blood, 2012
high expression of miR-3151 is an independent prognosticator for poor outcome in cytogenetically normal-AML and affects different outcome end points than its host gene, BAALC
Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia.
GeneRIF
de la Chapelle et al., Columbus, United States. In Proc Natl Acad Sci U S A, 2012
identify a heritable genomic feature predisposing to overexpression of an oncogene (BAALC), thereby possibly leading to enhanced AML leukemogenesis
Histone post-translational modifications associated to BAALC expression in leukemic cells.
GeneRIF
Damante et al., Udine, Italy. In Biochem Biophys Res Commun, 2012
These findings indicate that BAALC gene is "paused" and that in leukemia cells its transcription can be activated or repressed by mechanisms acting on epigenetic marks.
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
GeneRIF
Nordic Society of Pediatric Hematology and Oncology (NOPHO) et al., Göteborg, Sweden. In Blood, 2011
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia.
Impact
Heuser et al., Hannover, Germany. In J Clin Oncol, 2011
The prognostic impact of DNMT3A mutations was evaluated in the context of other clinical prognostic markers and genetic risk factors (cytogenetic risk group; mutations in NPM1, FLT3, CEBPA, IDH1, IDH2, MLL1, NRAS, WT1, and WT1 SNPrs16754; expression levels of BAALC, ERG, EVI1, MLL5, MN1, and WT1).
Prognostic importance of histone methyltransferase MLL5 expression in acute myeloid leukemia.
Impact
Heuser et al., Hannover, Germany. In J Clin Oncol, 2011
PATIENTS AND METHODS: MLL5 transcript levels from 509 patients with AML who were treated in multicenter trials AML SHG 0199 and AML SHG 0295 and 48 healthy volunteers were analyzed by real-time reverse-transcription polymerase chain reaction in the context of other molecular markers (NPM1, FLT3, CEBPA, IDH1/IDH2, NRAS, KIT, MN1, BAALC, ERG, and WT1).
[Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].
Review
Xu et al., Shanghai, China. In Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2010
The review focuses on research advances abroad in this field including gene mutations suggesting bad prognosis such as FMS-related tyrosine kinase 3 gene mutation, Baalc gene and ETS-related gene hyperexpression, Wilms' tumor gene mutation and other gene mutations as well as gene mutations suggesting good prognosis such as nucleophosmin gene mutation, mixed lineage leukemia-partial tandem duplication, CCAAT/enhancer-binding protein α gene mutation.
The role of molecular tests in acute myelogenous leukemia treatment decisions.
Review
Stone et al., Boston, United States. In Curr Hematol Malig Rep, 2010
The molecular markers with prognostic impact include mutations in FLT3, NPM1, MLL, WT1, c-KIT, and expression levels of BAALC, NM1, ERG, and CXCR4.
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Impact
Bloomfield et al., Columbus, United States. In J Clin Oncol, 2010
These profiles were characterized by upregulation of HOX genes and their embedded microRNAs and downregulation of the prognostically adverse MN1, BAALC, and ERG genes.
Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia.
Review
Valk et al., Rotterdam, Netherlands. In Cancer Treat Res, 2009
These molecular abnormalities include mutations (e.g., in FLT3, c-KIT, and NPM1), partial duplications (e.g., of MLL and FLT3), and abnormal expression of pathogenetic genes (e.g., EVI1, WT1, BCL2, MDR1, BAALC, and ERG).
ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Impact
Bohlander et al., München, Germany. In J Clin Oncol, 2009
In addition to the well-known influence of FLT3, NPM1, and CEBPA mutations, high transcript levels of the ERG, BAALC, and MN1 genes have been associated with inferior outcomes, but the relative importance of these risk markers remains to be defined.
Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
Review
Tse et al., Aurora, United States. In J Hematol Oncol, 2008
Molecular risk stratification for NC-AML patients may be possible due to mutations of NPM1, FLT3, MLL, and CEBPalpha as well as alterations in expression levels of BAALC, MN1, ERG, and AF1q.
The challenge of risk stratification in acute myeloid leukemia with normal karyotype.
Review
Aljurf et al., Riyadh, Saudi Arabia. In Hematol Oncol Stem Cell Ther, 2008
Emerging evidence reveals that at the submicroscopic level, AML with normal cytogenetics may carry poor prognostic genetic lesions or "molecular signatures" as is the case with FLT3 mutations and overexpression of BAALC, ERG or MN1, or may have aberrations that predict better risk as is the case with isolated NPM1 or CEBPA mutations.
share on facebooktweetadd +1mail to friends